Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinoma-Reference-Cited by-同舟云学术

Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinoma

Published:2022-12-26 Issue: Volume: Page:
ISSN:0300-8177
Container-title:Molecular and Cellular Biochemistry
language:en
Short-container-title:Mol Cell Biochem

Author:

Matsumoto Jun^ORCID,Nishimoto Anzu,Watari Shogo,Ueki Hideo,Shiromizu Shoya,Iwata Naohiro,Takeda Tatsuaki,Ushio Soichiro,Kajizono Makoto,Fujiyoshi Masachika,Koyama Toshihiro,Araki Motoo,Wada Koichiro,Zamami Yoshito,Nasu Yasutomo,Ariyoshi Noritaka

Funder

JSPS KAKENHI

Research Foundation of Pharmaceutical Science

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Clinical Biochemistry,Molecular Biology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11010-022-04637-4.pdf

Reference39 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

2. Du Z, Chen W, Xia Q, Shi O, Chen Q (2020) Trends and projections of kidney cancer incidence at the global and national levels, 1990–2030: a Bayesian age-period-cohort modeling study. Biomark Res 8:16. https://doi.org/10.1186/s40364-020-00195-3

3. Allain EP, Rouleau M, Lévesque E, Guillemette C (2020) Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression. Br J Cancer 122:1277–1287. https://doi.org/10.1038/s41416-019-0722-0

4. Guillemette C, Lévesque É, Rouleau M (2014) Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin Pharmacol Ther 96:324–339. https://doi.org/10.1038/clpt.2014.126

5. Ge Y, Chen S, Mu W, Ba Q, Li J, Chen P et al (2019) Epigenetic regulation of UDP-Glucuronosyltransferase by microRNA-200a/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma. Cancer Lett 454:14–25. https://doi.org/10.1016/j.canlet.2019.03.030